7 October 2019 - Medicines which can be used to treat lymphoma, lung cancer, breast cancer and psoriasis have today been accepted by the SMC for use by NHSScotland.

Axicabtagene ciloleucel (Yescarta) for lymphoma was accepted following consideration through SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.

Pembrolizumab (Keytruda) for metastatic non-squamous non-small cell lung cancer (NSCLC) was also accepted following consideration through PACE.

Read SMC press release